Stock Info: As on

NO DATA AVAILABLE

NO DATA AVAILABLE


Stock Exchange

Key Statistics

Total Assets
Total Assets


Company Curr Price Prev. Close Change% W's Low/High
Company Curr Price Prev. Close Change% W's Low/High
More
No Data AVAILABLE

Stock Held By Mutual Fund Schemes

Infosys Finacle partners with Niki.ai

Infosys Finacle part of EdgeVerve Systems, a wholly-owned subsidiary of Infosys has partnered with Niki.ai, a FinTech start-up to offer chat based commerce to banking customers. With this partnership, Finacle solution suite will be available with Niki.ai's chat-based virtual assistant-Niki. This offering will enable banks to offer its customers a virtual banking assistant for shopping products and services. The joint solution from Finacle and Niki.ai will provide a smart-purchasing chatbot by leveraging natural language processing and machine learning to converse with customers and perform online transactions. The bot will comprehend natural speech text in the context of the customer and will deliver personalized suggestions. The solution will provide banks an opportunity to initiate two-way automated intelligent conversations with customers. Meanwhile, shares of the company closed trading at Rs 911.30 apiece, up 0.31 per cent from the previous close on BSE.

19-09-2017 16:56

Shriram Transport Finance raises Rs 50 cr via bonds

Shriram Transport Finance Company Ltd said it has raised Rs 50 crore by issuing Secured Redeemable Rated Listed Non-Convertible Debenture on private placement basis. “The Allotment Committee - NCDs of the Company in its meeting held today, approved and allotted 500 Secured Redeemable Rated Listed Non-Convertible Debenture of face value of Rs.10,00,000/- (Rupees Ten Lakh only) each, aggregating to Rs. 50 crore on private placement basis,” the company said in a filing to the Bombay Stock Exchange. The bonds with a tenor of 3 years, 11 months and 29 days, carries a coupon rate of 7.60 per cent per annum. Meanwhile, shares of the company closed trading at Rs 1072.65 apiece, down 1.27 per cent from the previous close on BSE.

19-09-2017 16:14

Tata Chemicals sells shares of Tata Global Beverages

Tata Group entity, Tata Chemicals said that it has sold entire shareholding of 4,31,75,140 equity shares of Tata Global Beverages to Tata Sons through a block deal. “The Company has today, i.e., September 19, 2017, sold 4,31,75,140 Equity Shares of face value of Rs. 1/- each of Tata Global Beverages Limited to Tata Sons Limited at price of Rs. 213.35 per share,” it said in a filing to the Bombay Stock Exchange. The chemical company sold these shares at a price of Rs 213.35 per share (excluding brokerage and STT). Promoter group's shareholding stood at 35.76 per cent stake in Tata Global as of June 2017, including Tata Sons' stake of 23.5 per cent that increased to over 30 per cent post block deal. Meanwhile, shares of Tata Chemicals closed trading at Rs 656.95 apiece, up 2.24 per cent from the previous close on BSE.

19-09-2017 15:55

KPTL raises Rs 100 cr on private placement basis

Kalpataru Power Transmission Ltd said that it has raised Rs 100 crore by issuing Non-Convertible Debentures on private placement basis. “The executive committee of board of directors of the company at its meeting held today has approved issuance of listed, rated, unsecured redeemable taxable non convertible debentures of Rs 100 crore on private placement basis,” the company said in a filing to the Bombay Stock Exchange. The bonds carrying a coupon rate of 8.11 per cent p.a. are proposed to be listed on wholesale debt market segment of BSE Ltd. The debentures having a tenure of 5 years from the deemed date of allotment will mature on 27th September 2022, the filing added. Meanwhile, shares of the company closed trading at Rs 362.50 apiece, up 2.13 per cent from the previous close on BSE.

19-09-2017 15:46

Cadila Healthcare enters into agreement with Pharm Aid

Cadila Healthcare Limited, an innovation-driven global healthcare company has said that it has entered into an exclusive agreement for the technology know-how for varicella vaccine production in the Russian Federation with Pharm Aid Ltd., headquartered in Russia. The exclusive agreement was signed at the BIOTECHMED conference in Gelendzhik, Russia. Pharm Aid Ltd, has been set up by Nacimbio together with Ishvan Pharmaceuticals Ltd., for the localization of innovative vaccine production in Russia. Through this agreement, Zydus gains access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. With an absence of assured supply of indigenously manufactured varicella vaccine, this vaccine does not feature currently in the National Immunisation Programme. The agreement aims to bring in a continuous supply of vaccines which could be included in the critical childhood immunization programme. The demand is estimated at 3 million doses per annum in the Russian Federation alone. Meanwhile, shares of the company were trading at Rs 485.50 apiece, down 0.22 per cent from the previous close at 15:11 hours on BSE.

19-09-2017 15:05

Corporate Details

About Management

Registered Office

    

Registrar Details